SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328346.
  • 2
    Boers M, Verhoeven AC, Markusse HM, van der Laar MA, Westhovens R, van Denderen JR, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 30918.
  • 3
    Calgureni M, Pay S, Caliskaner Z, Apras S, Kiraz S, Ertenli I, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: 699704.
  • 4
    Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353: 156873.
  • 5
    O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 116470.
  • 6
    Landewe RB, Boers M, Verhoeven A, Westhovens R, van der Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2002; 46: 34756.
  • 7
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 8
    Fries JF. Re-evaluating the therapeutic approach to rheumatoid arthritis: the “sawtooth” strategy. J Rheumatol Suppl 1990; 22: 125.
  • 9
    Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 130815.
  • 10
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 11
    Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977; 18: 48191.
  • 12
    Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day; 1975.
  • 13
    Wolfe F, Hawley D. Remission of rheumatoid arthritis. J Rheumatol 1985; 12: 24552.
  • 14
    Mottonen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M. Outcome in patients with early rheumatoid arthritis treated according to the “sawtooth” strategy. Arthritis Rheum 1996; 39: 9961005.
  • 15
    Csuka ME, Carrera GF, McCarty DJ. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine: a followup study. JAMA 1986; 255: 23159.
  • 16
    O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity. Arthritis Rheum 2002; 46: 2835.
  • 17
    Landewe RB. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 2003; 48: 15.
  • 18
    Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al, for the FIN-RACo Trial Group. Delay to institution of therapy and induction of remission using single-drug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 8948.
  • 19
    Sokka T, Hannonen P. Utility of disease modifying antirheumatic drugs in “sawtooth” strategy: a prospective study of early rheumatoid arthritis up to 15 years. Ann Rheum Dis 1999; 58: 61822.
  • 20
    Kaarela K, Kautiainen H. Continuous progression of radiological destruction in seropositive rheumatoid arthritis. J Rheumatol 1997; 24: 12857.
  • 21
    Hulsmans HM, Jacobs JW, van der Heijde DM, van Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000; 43: 192740.
  • 22
    Jantti J, Kaarela K, Belt E, Kautiainen H. Incidence of severe outcome in rheumatoid arthritis during 20 years. J Rheumatol 2002; 29: 68892.
  • 23
    Larsen A, Thoen J. Hand radiography of 200 patients with rheumatoid arthritis repeated after an interval of one year. Scand J Rheumatol 1987; 16: 395401.
  • 24
    Mottonen T. Prediction of erosiveness and rate of development of new erosion in early rheumatoid arthritis. Ann Rheum Dis 1988; 47: 64853.
  • 25
    Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 58591.
  • 26
    Van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 2634.
  • 27
    Paimela L. The radiographic criterion in the 1987 revised criteria for rheumatoid arthritis: reassessment in a prospective study of early disease. Arthritis Rheum 1992; 35: 2558.
  • 28
    Sokka TM, Kaarela K, Mottonen TT, Hannonen PJ. Conventional monotherapy compared with a sawtooth treatment strategy in the radiographic progression of rheumatoid arthritis over the first eight years. Clin Exp Rheumatol 1999; 17: 52732.
  • 29
    Albers JM, Paimela L, Kurki P, Eberhardt KB, Emery P, van 't Hof MA, et al. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60: 4538.
  • 30
    Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002; 41: 134656.
  • 31
    Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effects of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford) 2003; 42: 613.
  • 32
    Strand V, Sharp JT. Radiographic data from recent randomized controlled trials in rheumatoid arthritis: What have we learned? Arthritis Rheum 2003; 48: 2134.
  • 33
    Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception cohort. Arthritis Rheum 2003; 48: 4653.
  • 34
    Neva MH, Kauppi MJ, Kautiainen H, Luukkainen R, Hannonen P, Leirisalo-Repo M, et al, for the FIN-RACo Trial Group. Combination drug therapy retards the development of rheumatoid atlantoaxial subluxation. Arthritis Rheum 2000; 43: 2397401.